Nov 2024;37(8):2223-2232
Key regulatory points for Epitalon Australia compliance: Epitalon is not approved by the Therapeutic Goods Administration (TGA) as a registered medicine for human or veterinary use It is classified strictly for laboratory and research purposes, not for human consumption Supply, import, and handling of research peptides fall under Australian regulatory oversight, and institutions should confirm current scheduling status directly through TGA resources before procurement Any research involving human subjects must comply with Research Ethics Committee approval and applicable Good Clinical Practice standards Marketing or supplying Epitalon with therapeutic claims, or implying suitability for human treatment, falls outside permitted research-use classifications Researchers and institutions should treat Epitalon strictly as a laboratory reagent, ensuring internal documentation, handling protocols, and communications consistently reflect its research-only status
Reported adverse events are generally mild and local, such as transient injection-site redness, itching, or bruising
The epithelial tissue disorganization and crypt disorganization were divided into five categories according to the degree of disorganization of each tissue
Georges, R.I.) Mikey Ekenyre (Jr
